News › Clinical Practice, Industry News, Patient Care

FDA Clears CoolSculpting for Treatment of ‘Double Chin’

February 26, 2018

The U.S. Food and Drug Administ­ration has cleared CoolSculpting as the first and only non-surgical fat reduction technology for use to improve the appearance of lax tissue and submental fat treatments, or “double chin,” according to Allergan.
“Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking non-invasive aesthetic treatments,” said David Nicholson, chief research and development officer at Allergan. “A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73% of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.”
Read more at Skin Inc >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Texas Med Spa Medical Director, Owner Charged in 2023 IV Therapy Death
    • Allergan Aesthetics Pledges Donation for New Allē Member Referrals During Skin Cancer Awareness Month
    • Dermalogica Launches FDA-Cleared PRO Pen Microneedling System
    • Regenerative Aesthetics Is Evolving. Are You Keeping Up?
    • Influx Marketing Introduces Growthstack, a New All-In-One Growth Platform Built for Med Spas